Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01175980 · OUTCOME

Stable Disease Duration (SDD)

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma · Source last updated 2020-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
90% Confidence Interval
Time frame
Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months

What was measured

SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate.

Groups in this outcome

Treatment (Vorinostat)

Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Vorinostat)30

Reported measurements

Source class 1
Values in months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Vorinostat)11.4Not reported7.120.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7.1
        upper Limit
        20.5
        value
        11.4
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate.
dispersion Type
90% Confidence Interval
groups
  1. description
    Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO
    id
    OG000
    title
    Treatment (Vorinostat)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
title
Stable Disease Duration (SDD)
type
OTHER_PRE_SPECIFIED
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice